S15 Ep28: Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP

In today’s episode, we had the pleasure of speaking with Rahul Banerjee, MD, FACP, about the ongoing investigation of CELMoDs for multiple myeloma. Dr Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center, as well as an assistant professor in the Division of Hematology and Oncology at the University of Washington in Seattle. In our exclusive interview, Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with traditional immunomodulatory drugs (IMiDs) like lenalidomide (Revlimid) and pomalidomide (Pomalyst). He also noted strong preclinical and clinical data with CELMoDs, as well as their favorable safety profiles that include fewer immune and hematopoietic effects. Additionally, he explained that early data suggest that CELMoDs could replace traditional IMiDs, offering better long-term outcomes and fewer adverse effects.